Shares of Radius Health (NASDAQ: RDUS), a biopharmaceutical company, are soaring today in response to positive clinical-trial data. Investors excited about elacestrant, an experimental new cancer treatment Radius Health is developing in partnership with the Menarini Group, an Italian company, pushed the stock up 48.8% shortly after the market opened. Elacestrant is an experimental therapy for breast cancer patients who have tumors that express lots of estrogen receptors but lack receptors for human epidermal growth factor.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting